| Dr Charlotte N Lim, MD | |
|
975 Port Washington Rd, Grafton, WI 53024-9201 | |
| (262) 329-1400 | |
| Not Available |
| Full Name | Dr Charlotte N Lim |
|---|---|
| Gender | Female |
| Speciality | Undersea And Hyperbaric Medicine |
| Experience | 28 Years |
| Location | 975 Port Washington Rd, Grafton, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154343200 | NPI | - | NPPES |
| 100062256 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0011X | Preventive Medicine - Undersea And Hyperbaric Medicine | 66463 (Wisconsin) | Primary |
| 207Q00000X | Family Medicine | 66463 (Wisconsin) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Medical Center - Grafton | Grafton, WI | Hospital |
| Aurora St Lukes Medical Center | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
An Australian-led research team has demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma.
The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.
The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types.
Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.
Meat manufacturer Cargill Inc. is recalling nearly 36 million pounds of ground turkey linked to a California death and at least 78 other salmonella illnesses nationwide, company officials said. The U.S. Department of Agriculture (USDA) announced the Class I recall, with the highest health risk, late Wednesday. All of the recalled products were produced at the company's Springdale, Ark., plant.
› Verified 7 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
An Australian-led research team has demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma.
The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.
The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types.
Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.
Meat manufacturer Cargill Inc. is recalling nearly 36 million pounds of ground turkey linked to a California death and at least 78 other salmonella illnesses nationwide, company officials said. The U.S. Department of Agriculture (USDA) announced the Class I recall, with the highest health risk, late Wednesday. All of the recalled products were produced at the company's Springdale, Ark., plant.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charlotte N Lim, MD 3301 W Forest Home Ave, Milwaukee, WI 53215-2843 Ph: (414) 389-2233 | Dr Charlotte N Lim, MD 975 Port Washington Rd, Grafton, WI 53024-9201 Ph: (262) 329-1400 |
News Archive
An Australian-led research team has demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma.
The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.
The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types.
Rexahn Pharmaceuticals, Inc. has announced that it has received FDA approval to begin Phase II trials for Archexin, the Company's leading cancer compound, for the treatment of pancreatic cancer.
Meat manufacturer Cargill Inc. is recalling nearly 36 million pounds of ground turkey linked to a California death and at least 78 other salmonella illnesses nationwide, company officials said. The U.S. Department of Agriculture (USDA) announced the Class I recall, with the highest health risk, late Wednesday. All of the recalled products were produced at the company's Springdale, Ark., plant.
› Verified 7 days ago